Cancer Clinical Trials (CCT)
Ralph Meyer, Division Director
CCT houses the NCIC Clinical Trials Group (NCIC CTG), a national research group that develops, conducts, and analyses multi-institutional trials of cancer therapy. Over 60 institutions involved in cancer care in Canada and elsewhere participate in CTG studies. In addition, the CTG participates in international trials in North America, Europe and Australia.
The NCIC CTG has two main areas of study: investigational new drugs; and comparative randomized (phase III) trials. The NCIC CTG's role in investigational new drug trials is to provide a centralized focus of knowledge, expertise, and experience to help Canadian investigators compete successfully for access to promising and scientifically interesting new agents. The Phase III program develops and conducts randomized trials across the spectrum of adult malignancies.
Investigators at the NCIC CTG have played lead roles in the development of new methodology for study designs, assessment of response, and toxicity, which have become accepted internationally. In addition, it provides the organizational mechanism for collaboration in international trials.
Cancer Clinical Trials Division
Cancer Research Institute
1st Floor, 10 Stuart Street
Kingston, ON Canada K7L 3N6
For more information, please contact:
Dr. Ralph Meyer
NCIC Clinical Trials Group